Article

Travoprost approved as first-line IOP therapy

The FDA has approved once-daily travoprost ophthalmic solution 0.004% prescription eye drops (Travatan Z, Alcon Laboratories) as first-line treatment of elevated IOP associated with open-angle glaucoma or ocular hypertension

Huenenberg, Switzerland-The FDA has approved once-daily travoprost ophthalmic solution 0.004% prescription eye drops (Travatan Z, Alcon Laboratories) as first-line treatment of elevated IOP associated with open-angle glaucoma or ocular hypertension.

“The FDA approval for first-line use of [travoprost] solution will allow eye-care professionals to start [treating patients with] newly diagnosed glaucoma and ocular hypertension . . . with a product that is already well-received in the marketplace because of its efficacy and safety,” said Stuart Raetzman, Alcon’s vice president of global marketing and area president for the United States. “This approval also means that [travoprost] will be the first and only prostaglandin analogue approved by the FDA for first-line treatment of glaucoma patients that does not contain the preservative benzalkonium chloride.”

The company developed travoprost with a proprietary ionic-buffered preservative system (sofZia). The ophthalmic solution was introduced in the United States in 2006.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.